Ruxolitinib is not only the first, but also the only topical treatment available to counteract non-segmental vitiligo involving the face, in adults and adolescents aged 12 years and older. The treatment, which following the marketing authorization by the Italian Medicines Agency (AIFA) communicated in 2023, enjoys reimbursement, is the result of research by the biopharmaceutical company Incyte.
#Health #Incyte #specific #treatment #vitiligo
